Amneal Pharmaceuticals has launched oseltamivir
phosphate for oral suspension, the company's AB-rated therapeutic equivalent for Tamiflu, in a 6 mg/mL strength.
The World Health Organisation (WHO) has downgraded oseltamivir
(Tamiflu) due to uncertainty surrounding its clinical trials, bringing to a head concerns about data and drug stockpiling.
phosphate is intended for use in patients 2 weeks of age and older who have had flu symptoms for no more than 48 hours, and for prevention of influenza in patients 1 year of age and older.
The most commonly reported adverse effect of oseltamivir
is gastrointestinal discomfort including nausea and vomiting.
Neuraminidase inhibitors such as oseltamivir
and zanamivir are commonly used for stopping influenza virus infections.
Treatment of influenza virus infection with oral oseltamivir
reduces time to alleviation of symptoms in adults and children by approximately one day compared with placebo.
is the most important and effective drug for severe influenza infections.
A lively, and sometimes heated, debate has recently been conducted in the popular press (1) and medical literature (2-4) about the effectiveness of oseltamivir
, its usefulness in treating seasonal influenza, and the need for it to be stockpiled for use in a future influenza pandemic.
and zanamivir are competitive inhibitors for the neuraminidase enzyme for the influenza virus.
The settlement allows Alvogen to market the oseltamivir
phosphate capsules before the pediatric exclusivity period expirs on 23rd February 2017.
New clinical research has suggested that an herbal medicinal product containing a proprietary combination of a concentrated echinacea herb and root extract is as effective as the conventional antiviral medicine oseltamivir
(Tamiflu) in the early treatment of influenza.
Consistent with the American Academy of Pediatrics and the Centers for Disease Control and Prevention guidelines, the authors recommend empiric oseltamivir
for a child with influenzalike illness who has a condition that places them at risk for influenza complications, particularly if the suspected agent is the pandemic H1N1 virus.